Logo Image

Esther Kim, MD

Articles by Esther Kim, MD

3 experts are featured in this series.

Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

ByEhsan Rahimy, MD,David G. Miller, MD ,Esther Kim, MD

Ehsan Rahimy, MD; David G. Miller, MD; and Michael Klufas, MD, discuss how real-world treatment strategies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.

3 experts are featured in this series.

Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

ByEhsan Rahimy, MD,David G. Miller, MD ,Esther Kim, MD

Ehsan Rahimy, MD; David G. Miller, MD; and Michael Klufas, MD, discuss how real-world treatment strategies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.

3 experts are featured in this series.

Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases

ByEhsan Rahimy, MD,David G. Miller, MD ,Esther Kim, MD

Ehsan Rahimy, MD; David G. Miller, MD; and Esther Kim, MD, discuss how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases such as AMD and DME, while highlighting the benefits of newer agents such as aflibercept 8 mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.

3 experts are featured in this series.

Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases

ByEhsan Rahimy, MD,David G. Miller, MD ,Esther Kim, MD

Ehsan Rahimy, MD; David G. Miller, MD; and Esther Kim, MD, discuss how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases such as AMD and DME, while highlighting the benefits of newer agents such as aflibercept 8 mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.

Latest Updated Articles